Tuberculosis
|
0.100 |
Biomarker
|
disease |
BEFREE |
We assessed the number of patients that developed typical (Mycobacterium tuberculosis [MTB]) and atypical mycobacterial infections (AMI) while on treatment with ruxolitinib by utilizing the United States Food and Drug Administration (FDA) adverse events reporting system (FAERS).
|
31699655 |
2020 |
Tuberculosis
|
0.100 |
Biomarker
|
disease |
BEFREE |
Despite efforts to promote bi-directional screening of TB and DM, the uptake of TB testing among pre-diabetes and diabetes cases was only 4.7%, while the uptake of DM testing among MTB positive cases was 21.8%.
|
30841929 |
2019 |
Tuberculosis
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
The lipolytic protein LipU was conserved in mycobacterium sp. including M. tuberculosis (MTB LipU) and M. leprae (MLP LipU).
|
29557724 |
2019 |
Tuberculosis
|
0.100 |
Biomarker
|
disease |
BEFREE |
We evaluated several novel methods including Xpert Mycobacterium tuberculosis/rifampicin (Xpert MTB/RIF) technology, quantitative fluorescence Polymerase Chain Reaction (qPCR) and High-Resolution Melting Curve (HRMC) in the diagnosis of superficial lymph node TB.
|
31333119 |
2019 |
Tuberculosis
|
0.100 |
Biomarker
|
disease |
BEFREE |
Identification of vaccine antigens (Ags) by considering Mtb genetic diversity is crucial for the development of improved TB vaccine.
|
30753099 |
2019 |
Tuberculosis
|
0.100 |
Biomarker
|
disease |
BEFREE |
The binding affinity of all the designed compounds for HIV-RT and Mycobacterium tuberculosis Enol Reductase (MTB InhA) was gauged by molecular docking studies which revealed crucial thermodynamic interactions governing their binding.
|
30574853 |
2019 |
Tuberculosis
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Effect of two alternative methods of pooling sputum prior to testing for tuberculosis with genexpert MTB/RIF.
|
31029099 |
2019 |
Tuberculosis
|
0.100 |
Biomarker
|
disease |
BEFREE |
In this study, two high-throughput TB PCR assays with combined antimicrobial resistance detection, Anyplex™ II MTB/MDR (Seegene) and RealTime MTB + RealTime MTB RIF/INH Resistance (Abbott Molecular), were evaluated for routine use in a clinical setting of low population and low TB prevalence in Finland.
|
30901113 |
2019 |
Tuberculosis
|
0.100 |
Biomarker
|
disease |
BEFREE |
Abbott RealTime MTB and MTB RIF/INH assays for the diagnosis of tuberculosis and rifampicin/isoniazid resistance.
|
30902741 |
2019 |
Tuberculosis
|
0.100 |
Biomarker
|
disease |
BEFREE |
Ability of Xpert MTB/RIF assay for rapid and simultaneous detection of MTB and RIF resistance in comparison with culture makes it a useful diagnostic tool in skeletal TB.
|
30880713 |
2019 |
Tuberculosis
|
0.100 |
Biomarker
|
disease |
BEFREE |
Mycobacterium tuberculosis (Mtb) protein tyrosine phosphatases A and B (PtpA and PtpB) have been recognized as potential molecular targets for the development of new therapeutic strategies against tuberculosis (TB).
|
29275228 |
2018 |
Tuberculosis
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Correlation of results of polymerase chain reaction for Mycobacterium tuberculosis (MTB PCR) with clinical features and treatment response in tubercular uveitis.
|
28665743 |
2018 |
Tuberculosis
|
0.100 |
Biomarker
|
disease |
BEFREE |
In efforts to discover Mycobacterium tuberculosis (Mtb) biomarkers we identified by mass spectroscopy a unique 21-mer Mtb peptide sequence (VVLGLTVPGGVELLPGVALPR) present in the urines of TB patients from Zimbabwe.
|
29306028 |
2018 |
Tuberculosis
|
0.100 |
Biomarker
|
disease |
BEFREE |
Abbreviations AR allergic rhinitis AM alveolar macrophage ATG autophagy-related CF cystic fibrosis CFTR cystic fibrosis transmembrane conductance regulator COPD chronic obstructive pulmonary disease CS cigarette smoke CSE cigarette smoke extract DC dendritic cell IH intermittent hypoxia IPF idiopathic pulmonary fibrosis ILD interstitial lung disease MAP1LC3B microtubule associated protein 1 light chain 3 beta MTB Mycobacterium tuberculosis MTOR mechanistic target of rapamycin kinase NET neutrophil extracellular traps OSA obstructive sleep apnea PAH pulmonary arterial hypertension PH pulmonary hypertension ROS reactive oxygen species TGFB1 transforming growth factor beta 1 TNF tumor necrosis factor.
|
29130366 |
2018 |
Tuberculosis
|
0.100 |
Biomarker
|
disease |
BEFREE |
World Health Organization (WHO) recommended Lateral Flow urine LipoArabinoMannan assay (LF-LAM) in immunocompromised patients; in 2010 WHO endorsed the use of Xpert Mycobacterium Tuberculosis/Rifampicin (MTB/RIF) test for rapid TB diagnosis but the assay is not used as screening test in all HIV+ patients irrespectively of symptoms due to cost and logistical barriers.
|
30024890 |
2018 |
Tuberculosis
|
0.100 |
Biomarker
|
disease |
BEFREE |
Compared to MTB culture, overall sensitivity and specificity of TB-LAMP were 55.4% (95 CI 44.1-66.3) and 98.0% (95 CI 94.3-99.6) respectively.
|
29466946 |
2018 |
Tuberculosis
|
0.100 |
Biomarker
|
disease |
BEFREE |
Cost-effectiveness study of the microbiological diagnosis of tuberculosis using geneXpert MTB/RIF<sup>®</sup>.
|
27445177 |
2018 |
Tuberculosis
|
0.100 |
Biomarker
|
disease |
BEFREE |
The data indicated that routine testing of respiratory specimens from patients with presumptive tuberculosis by the RealTi<i>me</i> MTB PCR assay improves the tuberculosis diagnostic yield and may reduce the time to antituberculosis treatment initiation.
|
29540457 |
2018 |
Tuberculosis
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
During the outbreak that lasted five months (January-June 2015), Mycobacterium kansassi and MTB were isolated from lung caseous granulomas in 1/7 and 3/7 TB suspicious animals respectively.
|
30245044 |
2018 |
Tuberculosis
|
0.100 |
Biomarker
|
disease |
BEFREE |
Xpert<sup>®</sup> MTB/RIF associated with improved treatment initiation among patients with smear-negative tuberculosis.
|
30606320 |
2018 |
Tuberculosis
|
0.100 |
Biomarker
|
disease |
BEFREE |
<i>Mycobacterium tuberculosis</i>/human immunodeficiency virus (MTB/HIV) coinfection presents a special challenge to the prevention and treatment of tuberculosis and HIV/AIDS.
|
28861087 |
2017 |
Tuberculosis
|
0.100 |
Biomarker
|
disease |
BEFREE |
Xpert MTB/RIF was similar to other NATs (TaqMan MTB and TRCRapid M.TB) in terms of performance.
|
27919693 |
2017 |
Tuberculosis
|
0.100 |
Biomarker
|
disease |
BEFREE |
XpertMycobacterium tuberculosis/rifampicin (Xpert MTB/RIF) assay has been endorsed by the World Health Organization (WHO) for diagnosis of extrapulmonary tuberculosis (EPTB), while the sensitivity and specificity have not been fully evaluated.
|
28708053 |
2017 |
Tuberculosis
|
0.100 |
Biomarker
|
disease |
BEFREE |
Earlier studies suggested that <i>Mycobacterium tuberculosis</i> (Mtb) proteins exported within the host macrophage play an essential role in tuberculosis pathogenesis.
|
28288970 |
2017 |
Tuberculosis
|
0.100 |
Biomarker
|
disease |
BEFREE |
The latter platform is now also equipped with the RealTi<i>m</i>e (RT) MTB and RealTi<i>m</i>e MTB RIF/INH assays for TB and first-line drug resistance screening but has not been evaluated in settings of HIV and TB coinfection.
|
28592547 |
2017 |